Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
API-AHAI
2024-513191-17-00Phase 2Authorised
- Sponsor
- Centre Hospitalier Universitaire Dijon Bourgogne
- Start
- Jul 2024
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial in autoimmune haemolytic anaemia (AIHA) comparing Apixaban prophylaxis with Enoxaparin prophylaxis (2 arms). Primary endpoint: Clinical venous thromboembolic events within 24 weeks. Planned start Jul 2024; status: authorised.
02
Drugs
apixabanenoxaparin
03
Conditions
autoimmune haemolytic anaemia (AIHA)
Beyond the preview
Go deeper on 2024-513191-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513191-17-00.